1-20 of 58
John Crown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

Gabriel Hortobagyi, Daniil Stroyakovsky, Denise Yardley, Chiun-Shen Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Miguel Martín, Sherene Loi, Binghe Xu, Sara Hurvitz, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Federico Parnizari, Farhat Ghaznawi, Zheng Li, Sorcha Waters, Arunava Chakravartty, Dennis Slamon
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): GS03-03.
https://doi.org/10.1158/1538-7445.SABCS23-GS03-03
Published: 02 May 2024
View articletitled, Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
Journal Articles

Abstract PO1-03-03: STEEP criteria v2.0 validation: A multi-trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival

Sara López-Tarruella, Marina Pollan, Ander Urriticoechea, Eva Carrasco, Gonzalo Spera, Miguel Martín, Begoña Bermejo, Linnea Chap, Manuel Ruíz - Borrego, John Crown, Jose Angel García-Sáenz, Arlene Chan, Angel Guerrero, Valerie Bee, Lourdes Calvo, Rodrigo Fresco, Andrea Blasco, Andrés Hernando, Dennis Slamon
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-03-03.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-03-03
Published: 02 May 2024
View articletitled, Abstract PO1-03-03: STEEP criteria v2.0 validation: A multi-trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival
Journal Articles

Abstract PO5-06-06: Tumor/stromal expression of CD3/CD8/PD-1/PD-L1 and overall survival (OS) in patients (pts) with metastatic (met) HER2+ breast cancer (BC)

Denis Collins, Janet McCormack, Laura Ivers, Jose Javier Berenguer-Pina, Jo Ballot, Cecily Quinn, Darko Skrobo, Alex Eustace, Naomi Walsh, Aurelie Fabre, John Crown
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-06-06.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-06-06
Published: 02 May 2024
View articletitled, Abstract PO5-06-06: Tumor/stromal expression of CD3/CD8/PD-1/PD-L1 and overall survival (OS) in patients (pts) with metastatic (met) HER2+ breast cancer (BC)
Journal Articles

Abstract PO5-02-04: Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)

Iseult Browne, Ronan McLaughlin, Catherine Weadick, Shane O'Sullivan, Steve Millen, Danial Hadi, Syed Bilal-Shah, Maha Al Sendhi, Michaela Higgins, John Crown, Ruth Prichard, Damian McCartan, Arnold Hill, Roisin Connolly, Sinead Noonan, Deirdre O'Mahony, Ciara O'Hanlon-Brown, Bryan Hennessy, Cecily Quinn, Catherine M. Kelly, Seamus O'Reilly, Patrick G. Morris, Janice Walshe
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-02-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-02-04
Published: 02 May 2024
View articletitled, Abstract PO5-02-04: Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
Journal Articles

Abstract PS16-10: SPATIAL IMMUNE CELL DISTRIBUTION CAN REFINE PROGNOSIS IN EARLY-STAGE ER+/HER2-/LN- BREAST CANCER

Zak Kinsella, Hannah Nyarko, Anna Blümel, Mairi Lucas, Daria Kalinska-Lysiak, Claudia Aura Gonzalez, Arman Rahman, Joanna Fay, Tony O'Grady, Verena Murphy, John Crown, Cathy Kelly, William Gallagher, Darran O'Connor
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS16-10.
https://doi.org/10.1158/1538-7445.SABCS23-PS16-10
Published: 02 May 2024
View articletitled, Abstract PS16-10: SPATIAL IMMUNE CELL DISTRIBUTION CAN REFINE PROGNOSIS IN EARLY-STAGE ER+/HER2-/LN- BREAST CANCER
Journal Articles

Abstract 7634: HER2 extracellular domain in serum samples from HER2+ metastatic breast cancer patients as a potential biomarker of progression-free survival

Debbie O'Reilly, Marc Nolan, Ausra Teiserskiene, Bryan T. Hennessy, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7634.
https://doi.org/10.1158/1538-7445.AM2024-7634
Published: 22 March 2024
View articletitled, Abstract 7634: HER2 extracellular domain in serum samples from HER2+ metastatic breast cancer patients as a potential biomarker of progression-free survival
Journal Articles

Abstract B034: Targeting the HER family/Src pathways in ovarian cancer

Neil T. Conlon, Elena Mörhle, Denis M. Collins, John Crown
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): B034.
https://doi.org/10.1158/1538-7445.OVARIAN23-B034
Published: 04 March 2024
View articletitled, Abstract B034: Targeting the HER family/Src pathways in ovarian cancer
Journal Articles

Abstract 4041: The EML4-ALK fusion protein mediates reduced sensitivity to the combination of neratinib and dasatinib

Myra E. Castel, Neil T. Conlon, Lisa D. Eli, Alvin Wong, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4041.
https://doi.org/10.1158/1538-7445.AM2023-4041
Published: 04 April 2023
View articletitled, Abstract 4041: The EML4-ALK fusion protein mediates reduced sensitivity to the combination of neratinib and dasatinib
Journal Articles

Abstract 3962: Development of selection-free HER4-mutated CRISPR/Cas9 knock-ins in cutaneous melanoma cell lines

Marta Valenti, Yonglun Luo, Neil T. Conlon, Lisa D. Eli, Alvin Wong, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3962.
https://doi.org/10.1158/1538-7445.AM2023-3962
Published: 04 April 2023
View articletitled, Abstract 3962: Development of selection-free HER4-mutated CRISPR/Cas9 knock-ins in cutaneous melanoma cell lines
Journal Articles

Abstract 5787: Modelling the spatial heterogeneity of CD45-positive tumor infiltrating lymphocytes in early-stage, estrogen receptor-positive breast cancer

Zak Kinsella, Anna Blümel, Mairi Lucas, Andreas Lindner, Claudia A. Gonzalez, Arman Rahman, Joanna Fay, Tony O'Grady, Verena Murphy, John Crown, Cathy Kelly, William Gallagher, Darran O'Connor
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5787.
https://doi.org/10.1158/1538-7445.AM2023-5787
Published: 04 April 2023
View articletitled, Abstract 5787: Modelling the spatial heterogeneity of CD45-positive tumor infiltrating lymphocytes in early-stage, estrogen receptor-positive breast cancer
Journal Articles

Abstract P5-02-11: Immune cell profile of tumors from patients with metastatic (met) HER2+ breast cancer (BC) with < 30 months overall survival (OS)

Denis M. Collins, Janet McCormack, Laura P. Ivers, Jose Javier Berenguer Pina, Jo Ballot, Cecily Quinn, Darko Skrobo, Alex J. Eustace, Naomi Walsh, Aurelie Fabre, John Crown
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-11.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-11
Published: 01 March 2023
View articletitled, Abstract P5-02-11: Immune cell profile of tumors from patients with metastatic (met) HER2+ breast cancer (BC) with &lt; 30 months overall survival (OS)
Journal Articles

Abstract P6-12-09: Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines

Debbie O’Reilly, Lisa D. Eli, Alvin Wong, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-12-09.
https://doi.org/10.1158/1538-7445.SABCS22-P6-12-09
Published: 01 March 2023
View articletitled, Abstract P6-12-09: Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines
Journal Articles

Abstract P5-02-10: In-silico approaches that detect immune contexture to trastuzumab response in neo-adjuvant studies

Dalal AlSultan, Alex J. Eustace, Stephen F. Madden, John Crown
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-10.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-10
Published: 01 March 2023
View articletitled, Abstract P5-02-10: In-silico approaches that detect immune contexture to trastuzumab response in neo-adjuvant studies
Journal Articles

Abstract P3-07-16: Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models

Amira F. Mahdi, Niall Ashfield, Neil T. Conlon, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-16.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-16
Published: 01 March 2023
View articletitled, Abstract P3-07-16: Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models
Journal Articles

Abstract P1-11-10: Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

Niall Ashfield, Amira F. Mahdi, Neil T. Conlon, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P1-11-10.
https://doi.org/10.1158/1538-7445.SABCS22-P1-11-10
Published: 01 March 2023
View articletitled, Abstract P1-11-10: Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines
Journal Articles

Abstract P1-11-09: Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer

John Crown, Denis M. Collins, Alex J. Eustace, Maccon Keane, Linda Coate, John Kennedy, Seamus O’Reilly, Catherine Kelly, Miriam O’Connor, Michael J. Martin, Conleth Murphy, Karen Duffy, Janice Walshe, Thamir Mahgoub, Giuseppe Gullo, Brian Moulton, Alberto Alvarez-Iglesias, Imelda Parker, Bryan Hennessy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P1-11-09.
https://doi.org/10.1158/1538-7445.SABCS22-P1-11-09
Published: 01 March 2023
View articletitled, Abstract P1-11-09: Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer
Journal Articles

Abstract 3333: Pre-clinical investigation of neratinib plus dasatinib in breast cancer

Neil T. Conlon, Sandra Roche, Fiona O'Neill, Justine Meiller, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3333.
https://doi.org/10.1158/1538-7445.AM2022-3333
Published: 15 June 2022
View articletitled, Abstract 3333: Pre-clinical investigation of neratinib plus dasatinib in breast cancer
Journal Articles

Abstract 2717: Exploring immune contexture using computational approaches in HER2-positive breast cancer

Dalal AlSultan, Alex J. Eustace, Stephen F. Madden, John Crown
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2717.
https://doi.org/10.1158/1538-7445.AM2022-2717
Published: 15 June 2022
View articletitled, Abstract 2717: Exploring immune contexture using computational approaches in HER2-positive breast cancer
Journal Articles

Abstract 3988: Identification of HER4 mutations with potential as biomarkers of response to neratinib

Marta Valenti, Neil T. Conlon, Lisa D. Eli, Irmina Diala, John Crown, Denis M. Collins
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3988.
https://doi.org/10.1158/1538-7445.AM2022-3988
Published: 15 June 2022
View articletitled, Abstract 3988: Identification of HER4 mutations with potential as biomarkers of response to neratinib
Journal Articles

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Debbie O'Reilly, Nicola Gaynor, Neil Conlon, Irmina Diala, Lisa D Eli, John Crown, Denis M Collins
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-28.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-28
Published: 15 February 2022
View articletitled, Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines